Bioscience Animal Health PCL
Bioscience Animal Health Public Company Limited manufactures and distributes pharmaceutical supplies, devices, and equipment in Thailand. The company offers bioscience products, such as antibiotics, additives, injections, mold inhibitors, water-soluble products, vaccines, hormones, and Bismix B and SD series. It also provides products for livestock and pets, as well as trading services. The compa… Read more
Bioscience Animal Health PCL (BIS) - Total Assets
Latest total assets as of September 2025: ฿1.27 Billion THB
Based on the latest financial reports, Bioscience Animal Health PCL (BIS) holds total assets worth ฿1.27 Billion THB as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioscience Animal Health PCL - Total Assets Trend (2017–2024)
This chart illustrates how Bioscience Animal Health PCL’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bioscience Animal Health PCL - Asset Composition Analysis
Current Asset Composition (December 2024)
Bioscience Animal Health PCL's total assets of ฿1.27 Billion consist of 81.4% current assets and 18.6% non-current assets.
| Asset Category | Amount (THB) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ฿0.00 | 10.2% |
| Accounts Receivable | ฿388.10 Million | 31.0% |
| Inventory | ฿264.71 Million | 21.1% |
| Property, Plant & Equipment | ฿0.00 | 0.0% |
| Intangible Assets | ฿6.44 Million | 0.5% |
| Goodwill | ฿0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Bioscience Animal Health PCL's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioscience Animal Health PCL's current assets represent 81.4% of total assets in 2024, an increase from 66.4% in 2017.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2024, up from 3.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 31.0% of total assets.
Bioscience Animal Health PCL Competitors by Total Assets
Key competitors of Bioscience Animal Health PCL based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩123.42 Billion |
|
Xiwang Foodstuffs Co Ltd
SHE:000639
|
China | CN¥6.08 Billion |
|
Nanfang Black Sesame Group Co Ltd
SHE:000716
|
China | CN¥4.57 Billion |
|
CNFC Overseas Fishery Co Ltd
SHE:000798
|
China | CN¥5.88 Billion |
|
Henan Shuanghui Investment & Development Co Ltd
SHE:000895
|
China | CN¥40.64 Billion |
|
Xinjiang Chalkis Co Ltd
SHE:000972
|
China | CN¥1.25 Billion |
|
Daehan Flour Mills Co Ltd
KO:001130
|
Korea | ₩1.61 Trillion |
Bioscience Animal Health PCL - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Bioscience Animal Health PCL generates 1.86x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Bioscience Animal Health PCL generates $5.19 in net profit.
Bioscience Animal Health PCL - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 2.70 | 1.13 |
| Quick Ratio | 1.70 | 1.93 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ฿619.43 Million | ฿ 589.72 Million | ฿ 73.53 Million |
Bioscience Animal Health PCL - Advanced Valuation Insights
This section examines the relationship between Bioscience Animal Health PCL's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.77 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | ฿1.25 Billion |
| Market Capitalization | $4.82 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioscience Animal Health PCL's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bioscience Animal Health PCL's assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bioscience Animal Health PCL (2017–2024)
The table below shows the annual total assets of Bioscience Animal Health PCL from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ฿1.25 Billion | +2.00% |
| 2023-12-31 | ฿1.23 Billion | +13.17% |
| 2022-12-31 | ฿1.09 Billion | +18.06% |
| 2021-12-31 | ฿919.11 Million | +12.82% |
| 2020-12-31 | ฿814.63 Million | +161.52% |
| 2019-12-31 | ฿311.50 Million | -5.57% |
| 2018-12-31 | ฿329.86 Million | -1.15% |
| 2017-12-31 | ฿333.71 Million | -- |